Drug intelligence / Profile preview

Kidofen Duo

Development stage
Unknown
Lead developer
Aflofarm
Modality
Small Molecules
Administration
Oral
01

Overview

Kidofen Duo is a prescription pediatric oral suspension developed by Aflofarm Farmacja Polska that combines two active ingredients: ibuprofen (100 mg) and paracetamol (125 mg) per 5 ml. It is indicated for the short-term treatment of fever and mild to moderate pain of various origins (including post-operative pain) in children aged 2 years and older, particularly when monotherapy with paracetamol or ibuprofen is insufficient. Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase enzymes (COX-1 and COX-2), thereby reducing the production of pro-inflammatory prostaglandins. Paracetamol acts as an analgesic and antipyretic, with a mechanism of action thought to involve the inhibition of COX-3 in the central nervous system. The product is marketed as the first such combination in a pediatric suspension form in Europe.

Brand names
Kidofen Duo
Other names
paracetamol + ibuprofen pediatric suspensionacetaminophen + ibuprofenibuprofen + paracetamol pediatric suspension
02

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)COX-3 (Prostaglandin-endoperoxide synthase 1 splice variant)

Beyond the preview

Go deeper on Kidofen Duo.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kidofen Duo.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call